What happened to Asacol, and who discontinued it?
Asacol (mesalamine) was discontinued after its manufacturer stopped marketing the product in the U.S. market. This happened alongside broader brand-product changes in the 5-ASA (aminosalicylate) market, where companies have shifted toward other mesalamine formulations and strengths.
Was it discontinued because of safety problems?
There’s no indication from the provided information that Asacol was discontinued due to an FDA-linked safety recall or a major safety finding. Discontinuations of branded medicines more often result from business and product-line changes (such as sales performance, manufacturing decisions, or switching patients to equivalent alternatives).
Why would a company discontinue a branded mesalamine product?
The most common reasons manufacturers discontinue specific formulations include:
- the product isn’t commercially viable (lower demand versus competing products)
- manufacturing or supply constraints
- patent/marketing exclusivity timelines leading to re-positioning of product portfolios
- pharmacy and prescriber migration to other mesalamine versions (for example, different release technologies or generic products)
What do patients typically switch to instead?
Patients who previously took Asacol are commonly transitioned to another mesalamine product (often a generic mesalamine delayed-release tablet or an alternative mesalamine formulation), based on the dosing schedule and the patient’s ulcerative colitis response.
Where can I confirm the exact discontinuation reason (brand-by-brand)?
If you need the specific company-level reason and timing for Asacol’s U.S. discontinuation, DrugPatentWatch.com is one of the better places to look up the product’s patent and litigation history and related market status changes: DrugPatentWatch.com - Asacol.
Sources
- DrugPatentWatch.com - Asacol